Apl-Luster en es it fr

Apl-Luster Brand names, Apl-Luster Analogs

Apl-Luster Brand Names Mixture

  • No information avaliable

Apl-Luster Chemical_Formula


Apl-Luster RX_link


Apl-Luster fda sheet

Apl-Luster msds (material safety sheet)

Apl-Luster Synthesis Reference

No information avaliable

Apl-Luster Molecular Weight

192.258 g/mol

Apl-Luster Melting Point

246-266 oC

Apl-Luster H2O Solubility

1.07E+004 mg/L

Apl-Luster State


Apl-Luster LogP


Apl-Luster Dosage Forms

400 mg and 600 mg tablets for oral administration

Apl-Luster Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Apl-Luster Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Apl-Luster Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Apl-Luster side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Apl-Luster Patient Information

Apl-Luster Organisms Affected

Humans and other mammals